6-K filed May 18, 2026 at 07:00 ET
Compugen reported Q1 2026 results with revenue of $2.2M (vs $2.3M in Q1 2025) and net loss of $7.7M ($0.08/share) vs $7.2M ($0.08/share) in the prior year. Cash and equivalents stood at $134.9M with runway into 2029. Clinical milestones remain on schedule: COM701 MAIA-ovarian interim analysis by Q1 2027, AstraZeneca advancing rilvegostomig across 11 Phase 3 trials, and Gilead-partnered GS-0321 Phase 1 progressing. The filing is a routine quarterly update with no-surprise update with no material financial deviation from the prior period.